Category Archives: Non classé

Virnext and the academic laboratory VirPath announce the grant by the INPI of their patent in partnership with Signia Therapeutics for the repurposing of diltiazem as a modulator of the innate antiviral defence and its combination with current antivirals targeting SARS-CoV-2 variants.Licensed to our spin-off Signia Therapeutics this patent expands the company’s portfolio and highlights the strength of the SIGNATURA® platform for drug identification and repurposing as innovative broad-spectrum...

Licensed to our spin-off Vaxxel, the invention relates on a proprietary recombinant hMPV strain used as a versatile live-attenuated viral vaccine platform that can express several antigens of interest. Based on the Metavac® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus and human Metapneumovirus. This innovation is issued from a very fruitful collaboration with Dr. GuyBoivin's team LVMC at the Centre de recherche du...

This consortium is part of the partnership dynamic that we initiated in November 2020 with the Auvergne-Rhône-Alpes Region, the Lyonbiopôle competitiveness cluster and the company VirHealth by implementing the first studies in Europe to evaluate in a test chamber the performance of several air treatment devices in an atmosphere contaminated by the infectious SARS-CoV-2 virus. On the basis of the experimental results obtained and previous technical knowledge of these devices, the Auvergne-Rhôn...

VirNext provides expertise in the field of respiratory viruses (influenza, pneumoviruses, adenovirus, rhinovirus, coronaviruses and all SARS-CoV-2 variants of interest) and a large panel of technologies including egg and cell-based process of virus and vaccine antigen production, and several in vitro and in vivo preclinical models of infection. Here under is a reconstructed human airway epithelium MucilAir (Epithelix) infected by the SARS-CoV-2 B.1.617.2 Delta strain observed by confocal micr...

This study reports a biotechnological approach for the large-scale production of sialylated multivalent solid lipid microparticles (SSLMs) that can saturate hemagglutinins and prevent virus binding to host cells. This global approach combines a microbiological step leading to the production of sialylated maltodextrin chains by a metabolic engineered Escherichia coli strain, with a new in vitro enzymatic glycosylation method onto a long-chain alkyl glucoside, and the formulation of the final SSLM...

Our technological research platform VirNext is very proud of the spin-off VirexpR which has just reached a major step in its technological and strategic development plan. Thanks to its partner ASPIDA for the joint design and realization of this unique test bench in Europe which will allow VirexpR to position itself as an international reference in the management of microbiological and virological environmental pollution, and indoor air quality in confined spaces, whose health,...

The VirPath laboratory, Virnext and the LVMC Molecular and Cellular Virology Laboratory of the CHU de Québec-Université Laval Research Centre, are combining their strengths in the research of respiratory viral infections with the creation of RespiVir France - Canada, an International Associated Laboratory within the partnership framework of Université Claude Bernard Lyon 1 and Université Laval. The public announcement took place in Quebec City on 11 October 2022 in the presence of Ms EugÃ...

The emergence of SARS-CoV-2 have profoundly altered the epidemiology of major seasonal respiratory viruses (influenza, respiratory syncytial virus, human metapneumovirus and human rhinovirus). In this study, we studied and compare the mutual interactions between these pathogens in reconstituted human epithelial airway models (MucilAir®) by exploring different infection and superinfection scenarios. Our results suggest that the virus type and sequence of infections, with the specific nature of t...

This study reports that almost 5% of patients with critical influenza pneumonia studied internationally (cohort of 279 patients) had auto-Abs neutralizing IFN-α2 alone or with IFN-ω. By performing functional assays in our predictive models of influenza infection in reconstituted Human Airway Epithelium (HAE MucilAir), we further demonstrated that IFN-α2 treatment or IAV infection induced the expression of IFN-stimulated genes (ISGs), and that this expression was blocked by auto-Ab–positive...

The invention relates to the use of the DuckCelt®17 cell line (ECACC 09070703) and method for producing the Live-Attenuated human metapneumovirus-based vaccine platform METAVAC®. DuckCelt®-17 has been acquired by Vaxxel, a spin-off of the VirPath laboratory and Virnext. An exclusive worldwide license has been grant to Vaxxel for the use of METAVAC®.  This achievement is issued from a very fruitful collaboration with Dr. Guy Boivin’s team LVMC at the Centre de recherche du CHU de...